Literature DB >> 25606789

VEGF-trap aflibercept significantly improves long-term graft survival in high-risk corneal transplantation.

Thomas H Dohlman1, Masahiro Omoto, Jing Hua, William Stevenson, Sang-Mok Lee, Sunil K Chauhan, Reza Dana.   

Abstract

BACKGROUND: Graft failure because of immune rejection remains a significant problem in organ transplantation, and lymphatic and blood vessels are important components of the afferent and efferent arms of the host alloimmune response, respectively. We compare the effect of antihemangiogenic and antilymphangiogenic therapies on alloimmunity and graft survival in a murine model of high-risk corneal transplantation.
METHODS: Orthotopic corneal transplantation was performed in hemevascularized and lymph-vascularized high-risk host beds, and graft recipients received subconjunctival vascular endothelial growth factor (VEGF)-trap, anti-VEGF-C, sVEGFR-3, or no treatment, beginning at the time of surgery. Fourteen days after transplantation, graft hemeangiogenesis and lymphangiogenesis were evaluated by immunohistochemistry. The frequencies of Th1 cells in regional lymphoid tissue and graft-infiltrating immune cells were evaluated by flow cytometry. Long-term allograft survival was compared using Kaplan-Meier curves.
RESULTS: VEGF-trap significantly decreased graft hemangiogenesis as compared to the control group and was most effective in reducing the frequency of graft-infiltrating immune cells. Anti-VEGF-C and sVEGFR3 significantly decreased graft lymphangiogenesis and lymphoid Th1 cell frequencies as compared to control. VEGF-trap (72%), anti-VEGF-C (25%), and sVEGFR-3 (11%) all significantly improved in the 8-week graft survival compared to control (0%), although VEGF-trap was significantly more effective than both anti-VEGF-C (P < 0.05) and sVEGFR-3 (P < 0.05).
CONCLUSION: In a clinically relevant model of high-risk corneal transplantation in which blood and lymphatic vessels are present and treatment begins at the time of transplantation, VEGF-trap is significantly more effective in improving long-term graft survival as compared to anti-VEGF-C and sVEGFR-3, but all approaches improve survival when compared to untreated control.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25606789     DOI: 10.1097/TP.0000000000000512

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  34 in total

1.  Effect of sorafenib in a murine high risk penetrating keratoplasty model.

Authors:  Yang Kyung Cho; Eun Young Shin; Hironori Uehara; Balamurali K Ambati
Journal:  Int J Ophthalmol       Date:  2017-06-18       Impact factor: 1.779

2.  Update on the Management of High-Risk Penetrating Keratoplasty.

Authors:  Sayena Jabbehdari; Alireza Baradaran Rafii; Ghasem Yazdanpanah; Pedram Hamrah; Edward J Holland; Ali R Djalilian
Journal:  Curr Ophthalmol Rep       Date:  2017-02-02

Review 3.  Management of high-risk corneal transplantation.

Authors:  Antonio Di Zazzo; Ahmad Kheirkhah; Tulio B Abud; Sunali Goyal; Reza Dana
Journal:  Surv Ophthalmol       Date:  2016-12-22       Impact factor: 6.048

4.  Kinetics of Angiogenic Responses in Corneal Transplantation.

Authors:  Takenori Inomata; Alireza Mashaghi; Antonio Di Zazzo; Sang-Mok Lee; Homer Chiang; Reza Dana
Journal:  Cornea       Date:  2017-04       Impact factor: 2.651

5.  Regulatory T Cells Mediate Local Immunosuppression in Lymphedema.

Authors:  Gabriela D García Nores; Catherine L Ly; Ira L Savetsky; Raghu P Kataru; Swapna Ghanta; Geoffrey E Hespe; Stanley G Rockson; Babak J Mehrara
Journal:  J Invest Dermatol       Date:  2017-09-20       Impact factor: 8.551

Review 6.  Therapeutic approaches for induction of tolerance and immune quiescence in corneal allotransplantation.

Authors:  Maryam Tahvildari; Afsaneh Amouzegar; William Foulsham; Reza Dana
Journal:  Cell Mol Life Sci       Date:  2018-01-06       Impact factor: 9.261

7.  Tocilizumab promotes corneal allograft survival in rats by modulating Treg-Th17 balance.

Authors:  Xiao-Song Wu; Xiao-Li Lu; Jing Wu; Ming Ma; Jian Yu; Zhen-Yu Zhang
Journal:  Int J Ophthalmol       Date:  2019-12-18       Impact factor: 1.779

Review 8.  High-risk corneal allografts: A therapeutic challenge.

Authors:  Tian Yu; Vijayalakshmi Rajendran; May Griffith; John V Forrester; Lucia Kuffová
Journal:  World J Transplant       Date:  2016-03-24

Review 9.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

Review 10.  Alloimmunity and Tolerance in Corneal Transplantation.

Authors:  Afsaneh Amouzegar; Sunil K Chauhan; Reza Dana
Journal:  J Immunol       Date:  2016-05-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.